Cover Image
市場調查報告書

氟西汀的中國市場:2010∼2019年

Investigation Report on China Fluoxetine Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 353341
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
氟西汀的中國市場:2010∼2019年 Investigation Report on China Fluoxetine Market, 2010-2019
出版日期: 2016年02月29日 內容資訊: 英文 20 Pages
簡介

氟西汀為憂鬱症的治療藥由Eli Lilly and Company開發,1986年在比利時認證。美國1987年,中國1995年認證。這是選擇性血清再吸收抑制劑 (SSRI) 之一,用於治療成人憂鬱症和強迫症,神經性過食症,恐慌症等。中國國內的氟西汀市場預計2010∼2014年,以9.68%年複合成長率 (CAGR) 成長。2001年最初的專利屆滿以來,多數的產品上市。

本報告提供中國的氟西汀的市場相關分析,關於氟西汀的特徵和認證情形,整體市場規模,各企業、各劑型的市場佔有率,價格趨勢,主要製造商簡介,今後的市場成長預測等調查評估。

第1章 氟西汀的相關概念

  • 適應症
  • 全球市場的銷售情形

第2章 中國的氟西汀市場簡介

  • 中國國內的氟西汀的專利申請、核準情況
  • 主要製造商
  • 市場規模

第3章 中國國內的氟西汀銷售額分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 氟西汀的主要廠商的市場佔有率 (過去5年份)

  • 市場佔有率 (以金額為準)
  • 市場佔有率 (以數量為準)

第5章 中國國內的氟西汀的劑型 (過去5年份)

  • 各劑型的市場佔有率 (以金額為準)
  • 各劑型的市場佔有率 (以數量為準)

第6章 中國的醫院的氟西汀的參照價格

  • Patheon France (FR)
  • Shanghai Zhongxi Pharmaceutical Co., Ltd.
  • Shanxi C&Y Pharmaceutical Group Co., Ltd.
  • WATSON Pharmaceuticals (Changzhou) Co., Ltd.
  • Changzhou Siyao Pharmaceutical Co., Ltd.
  • Suzhou Chung-Hwa Pharmaceutical & Chemical Industrial Co., Ltd. (SCCPC)
  • Eli Lilly and Company (Britain)
  • Eli Lilly and Company (Spain)

第7章 中國國內的氟西汀的主要製造商 (過去5年份)

  • Patheon France (FR)
  • Shanghai Zhongxi Pharmaceutical Co., Ltd.
  • Shanxi C&Y Pharmaceutical Group Co., Ltd.
  • WATSON Pharmaceuticals (Changzhou) Co., Ltd.
  • Changzhou Siyao Pharmaceutical Co., Ltd.
  • Suzhou Chung-Hwa Pharmaceutical & Chemical Industrial Co., Ltd. (SCCPC)
  • Eli Lilly and Company

第8章 中國國內的氟西汀市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭模式的預測

圖表一覽

目錄
Product Code: 1602320

WHO predicts that by 2020, depression will probably become the second largest disease next to cardio-cerebrovascular disease. Every year, the suicide death toll of depression around the world is up to 1 million people and the amount of depression patients in China has reached 90 million. At present, the recognition rate of depression in our country is only 30% and the identified patients seeking medical advice is also 30%, which means less than 10% of the depressive patients were likely to utilize medical service. Clinical experience shows that 80% of the patients can achieve clinical cure, if having standard treatment, expect very few patients with refractory type, others will be improvement.

Original antidepressants Fluoxetine produced by Eli Lilly and Company was approved for the treatment of depression first in Belgium in 1986.

Fluoxetine is a kind of selective serotonin reuptake inhibitors (SSRI) antidepressants and its medicinal form is Fluoxetine hydrochloride. Eli Lilly and Company named their products "the optimal solution" (Prozac) which is used for the treatment of adult depression, obsessive-compulsive disorder and neurological bulimia in clinical practice as well as panic disorder with or without agoraphobe. At the end of 1987, Fluoxetine was approved by the U.S. Food and Drug Administration (FDA) to enter American market, and it entered the Chinese market on March 30, 1995. Eli Lilly and Company's patent for Prozac expired in August of 2001, since then there have appeared a large number of Fluoxetine drugs on the market.

There is a broad demand market of Fluoxetine in China. From 2010 to 2014, according to CRI's survey on sample hospitals, CAGR of Fluoxetine is up to 9.68%. Eli Lilly and Company (Spain), Eli Lilly and Company (Britain), Patheon (FR), Shanghai Zhongxi Pharmaceutical Co., Ltd, Changzhou Siyao Pharmaceutical Co., Ltd, SCCPC, WATSON Pharmaceuticals (Changzhou) Co., Ltd and Shanxi C&Y Pharmaceutical Group Co., Ltd. occupy large portion in the sales market. Measured by sales value, Lilly (Spain) enjoyed the highest market share, which reached 75% in 2014.

In China, with many people bearing a proliferation of pressure from life, learning and work, the amount of depressive patients will also present an increasing tendency. In conclusion, there exists huge potential in Chinese market demand for Fluoxetine.

Table of Contents

1. Related Concepts of Fluoxetine

  • 1.1. Indication
  • 1.2. Sales Situation of Global Market

2. Market Profile of Fluoxetine in China

  • 2.1. Patent and Approval Information of Fluoxetine in China
  • 2.2. Major Manufacturers
  • 2.3. Market Scale

3. Survey on Fluoxetine Sales Situation in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Fluoxetine Manufacturers in China, 2010-2014

  • 4.1. Market Share of Manufacturers by Sales Value
  • 4.2. Market Share of Manufacturers by Sales Volume

5. Survey on Dosage Forms of Fluoxetine in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Sales Price of Fluoxetine in Chinese Hospitals in 2014

  • 6.1. Patheon France (FR)
  • 6.2. Shanghai Zhongxi Pharmaceutical Co., Ltd.
  • 6.3. Shanxi C&Y Pharmaceutical Group Co., Ltd.
  • 6.4. WATSON Pharmaceuticals (Changzhou) Co., Ltd.
  • 6.5. Changzhou Siyao Pharmaceutical Co., Ltd.
  • 6.6. Suzhou Chung-Hwa Pharmaceutical & Chemical Industrial Co., Ltd. (SCCPC)
  • 6.7. Eli Lilly and Company (Britain)
  • 6.8. Eli Lilly and Company (Spain)

7. Major Production Enterprises of Fluoxetine in Chinese Market, 2010-2014

  • 7.1. Patheon France (FR)
  • 7.2. Shanghai Zhongxi Pharmaceutical Co., Ltd.
  • 7.3. Shanxi C&Y Pharmaceutical Group Co., Ltd.
  • 7.4. WATSON Pharmaceuticals (Changzhou) Co., Ltd.
  • 7.5. Changzhou Siyao Pharmaceutical Co., Ltd.
  • 7.6. Suzhou Chung-Hwa Pharmaceutical & Chemical Industrial Co., Ltd. (SCCPC)
  • 7.7. Eli Lilly and Company

8. Market Prospect of Fluoxetine in China, 2015-2019

  • 8.1. Prediction of Market Scale
  • 8.2. Prediction of Competition Pattern

Table of Selected Charts

  • Chart Patent Status of Fluoxetine in China
  • Chart Approval Information of Fluoxetine in China
  • Chart Sales Situation of Fluoxetine in China
  • Chart Sales Value of Fluoxetine in China, 2010-2014
  • Chart Sales Value of Fluoxetine in Some Regions of China, 2010-2014
  • Chart Sales Volume of Fluoxetine in China, 2010-2014
  • Chart Market Share of Corporations of TOP5 Fluoxetine Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Fluoxetine Produced by Eli Lilly and Company (Spain), 2010-2014
  • Chart Sales Value and Market Share of Fluoxetine Produced by Eli Lilly and Company (Britain), 2010-2014
  • Chart Sales Value and Market Share of Fluoxetine Produced by Patheon (FR) in China, 2010-2014
  • Chart Sales Value and Market Share of Fluoxetine Produced by Shanghai Zhongxi in China, 2010-2014
  • Chart Sales Value and Market Share of Fluoxetine Produced by Changzhou Siyao, 2010-2014
  • Chart Sales Value and Market Share of Fluoxetine Produced by other manufacturers in China, 2010-2014
  • Chart Sales Value and Market Share of Fluoxetine Tablet in China, 2010-2014
  • Chart Sales Value and Market Share of Fluoxetine Capsule in China, 2010-2014
  • Chart Sales Price of Fluoxetine Produced by Patheon France (FR) in Some Chinese Cities in 2014
  • Chart Sales Price of Fluoxetine Produced by Shanghai Zhongxi Pharmaceutical Co., Ltd. in Some Chinese Cities in 2014
  • Chart Sales Price of Fluoxetine Produced by Shanxi C&Y Pharmaceutical Group Co., Ltd. in Some Chinese Cities in 2014
  • Chart Sales Price of Fluoxetine Produced by WATSON Pharmaceuticals (Changzhou) Co., Ltd. in Some Chinese Cities in 2014
  • Chart Sales Price of Fluoxetine Produced by Changzhou Siyao Pharmaceutical Co., Ltd. in Some Chinese Cities in 2014
  • Chart Sales Price of Fluoxetine Produced by Suzhou Chung-Hwa Pharmaceutical & Chemical Industrial Co., Ltd. (SCCPC)in Some Chinese Cities in 2014
  • Chart Sales Price of Fluoxetine Produced by Eli Lilly and Company in Some Chinese Cities in 2014
Back to Top